Portal de investigación
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Kayser, Sabine
- Hanoun, Maher
- Stolzel, Friedrich
- Gil, Cristina
- Reinhardt, H. Christian
- Aguiar, Eliana
- Schafer-Eckart, Kerstin
- Burgues, Juan Miguel Bergua
- Steffen, Bjoern
- Bernal, Teresa
- Krause, Stefan W.
- Riaza, Rosalia
- Schliemann, Christoph
- Kaufmann, Martin
- Torres-Minana, Laura
- Hanel, Mathias
- Jost, Edgar
- Algarra, Jesus Lorenzo
- Crysandt, Martina
- Fransecky, Lars
- Cornago-Navascues, Javier
- Kraus, Sabrina
- Martinez-Lopez, Joaquin
- Einsele, Hermann
- Niemann, Dirk
- Neubauer, Andreas
- Seggewiss-Bernhardt, Ruth
- Scholl, Sebastian
- Klein, Stefan A.
- Schmid, Christoph
- Schaich, Markus
- Schmidt-Hieber, Martin
- Zukunft, Sven
- Ho, Anthony D.
- Platzbecker, Uwe
- Baldus, Claudia D.
- Muller-Tidow, Carsten
- Thiede, Christian
- Bornhauser, Martin
- Serve, Hubert
- Levis, Mark J.
- Rollig, Christoph
- Schlenk, Richard F.
Grupos
Abstract
We retrospectively studied 125 AML patients with trisomy 4 (median age at diagnosis, 58 years; range, 16-77 years) treated between 2000 and 2019 within a multicenter study. Trisomy 4 was the sole abnormality in 28 (22%) patients and additional abnormalities were present in 97 (78%) patients. Twenty-two (22%) and 15 (15%) of 101 tested patients harbored NPM1 and FLT3-ITD mutations. Two (3%) of 72 tested patients were CEBPA double mutated. Data on response to intensive anthracycline-based induction therapy were available in 119 patients. Complete remission (CR) was achieved in 67% (n=80) and early death rate was 5% (n=6). Notably, patients with trisomy 4 as sole abnormality had a CR rate of 89%. An allo-HCT was performed in 40 (34%) patients, of whom 19 patients were transplanted in CR1. Median follow-up of the intensively treated cohort was 5.76 years (95%-CI, 2.99-7.61 years). Five-year overall survival (OS) and relapse-free survival were 30% (95%-CI, 22-41%) and 27% (95%-CI, 18-41%). An Andersen-Gill regression model on OS revealed ELN favorable-risk (HR, 0.34; P=0.006) and trisomy 4 as sole abnormality (HR, 0.41 P=0.01) as favorable factors, whereas age with a difference of ten years (HR, 1.15, P=0.11), female gender (OR, 0.74; P=0.20) and allo-HCT (OR, 0.64; P=0.14) had no significant impact. In our cohort, patients with trisomy 4 as a sole abnormality had a high CR rate and favorable clinical outcome. Allo-HCT seems not to improve OS.
Datos de la publicación
- ISSN/ISSNe:
- 0390-6078, 1592-8721
- Tipo:
- Meeting Abstract
- Páginas:
- 34-41
- PubMed:
- 35678031
- Factor de Impacto:
- 2,528 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
HAEMATOLOGICA FERRATA STORTI FOUNDATION
Citas Recibidas en Web of Science: 6
Documentos
- No hay documentos
Filiaciones
Keywords
- PROGNOSTIC-SIGNIFICANCE; KARYOTYPE; ADULTS; TRANSPLANTATION; RECOMMENDATIONS; MITOXANTRONE; ABNORMALITY; DIAGNOSIS; MODEL; AML
Campos de Estudio
Cita
Kayser,S,Martinez,D,Hanoun,M,Stolzel,F,Gil,C,Reinhardt,HC,Aguiar,E et al. Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4. VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY:FERRATA STORTI FOUNDATION. 2022 p.p. 34-41.